Hill Olivia, Hughes Sarah, Singh Aakanksha, Ang-Rabanes Michael, Mogallapu Raja
Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, United States.
Front Psychiatry. 2025 May 1;16:1420316. doi: 10.3389/fpsyt.2025.1420316. eCollection 2025.
Glucagon-like peptide 1 (GLP-1) receptor agonists, medications commonly employed in the treatment of type 2 diabetes mellitus, have illustrated several additional benefits, including weight loss and potentially reduce addictive cravings. Several studies have indicated that GLP-1 receptor agonists may be effective in treating Alcohol Use Disorder (AUD), for which current pharmacologic therapies are often inadequate. Proposed mechanisms include modulation of dopaminergic transmission and reduced gastric emptying, both of which reduce alcohol craving and tolerance. This case report discusses dulaglutide's ability to reduce alcohol consumption. During a visit to an outpatient behavioral health clinic, a 44-year-old male was evaluated for weight loss. His medical history revealed a BMI of 41.8, hypertension, major depressive disorder, and pre-diabetes. The individual also reported the consumption of approximately ninety beers per month and was in the pre-contemplation phase of change. As part of the treatment plan, the patient was prescribed dulaglutide to manage pre-diabetes and facilitate weight loss. During subsequent appointments, the individual not only experienced weight loss but also noted a substantial reduction in alcohol cravings and consumption. However, following a lapse in insurance coverage the following year, the individual had to discontinue his dulaglutide, resulting in a return to previous drinking patterns. Future research should focus on confirming existing animal study results in humans, with the hope that GLP-1 receptor agonists can become a mainstay treatment for AUD.
胰高血糖素样肽-1（GLP-1）受体激动剂是常用于治疗2型糖尿病的药物，已显示出其他多种益处，包括体重减轻以及可能减少成瘾性渴望。多项研究表明，GLP-1受体激动剂可能有效治疗酒精使用障碍（AUD），而目前的药物治疗往往对此疗效不佳。提出的机制包括调节多巴胺能传递和减少胃排空，这两者均可减少对酒精的渴望和耐受性。本病例报告讨论了度拉糖肽减少酒精摄入的能力。在一次门诊行为健康诊所就诊时，一名44岁男性接受了体重减轻评估。他的病史显示体重指数为41.8，患有高血压、重度抑郁症和糖尿病前期。该个体还报告每月饮用约90瓶啤酒，且处于改变的未考虑阶段。作为治疗计划的一部分，为该患者开具了度拉糖肽以控制糖尿病前期并促进体重减轻。在随后的就诊中，该个体不仅体重减轻，还注意到对酒精的渴望和摄入量大幅减少。然而，在次年保险覆盖中断后，该个体不得不停用度拉糖肽，导致饮酒模式恢复到以前的状态。未来的研究应侧重于在人体中确认现有的动物研究结果，希望GLP-1受体激动剂能够成为治疗AUD的主要手段。
